We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
COVID-19 convalescent plasma donor characteristics, product disposition, and comparison with standard apheresis donors.
- Authors
Lasky, Baia; Goodhue Meyer, Erin; Steele, Whitney R.; Crowder, Lauren A.; Young, Pampee P.
- Abstract
<bold>Background: </bold>With coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) offering an early treatment option for COVID-19, blood collectors needed to quickly overcome obstacles to recruiting and qualifying eligible donors. We provide attributes of CCP donors and products and compare to standard donors and products.<bold>Study Design and Methods: </bold>Information on CCP donors was gathered from the American Red Cross qualification website through product collection. Data from 2019 for standard plasma/platelet apheresis (SA) and whole blood (WB) donor demographics and SA donations including product disposition and reactions were used for comparison.<bold>Results: </bold>Of almost 59 000 donors registering on the website, 75% reported an existing COVID-19 diagnostic polymerase chain reaction or an antibody test. The majority (56.2%) of 10 231 CCP donors were first-time donors in contrast to SA or WB donor populations, which were only 3.0% and 30.6%, respectively, first-time donors. The number of female donors was 12% higher than SA donors. Older (≥ 65 years) and younger (16-19 years) were comparatively underrepresented in CCP donors. Deferral (10.2%) and Quantity Not Sufficient rates (6.4%) for presenting CCP donations were higher than SA (8.2% and 1.1%, respectively). Human leukocyte antigen antibody reactivity was the highest cause of product loss for CCP donations vs SA donations (9.6% vs 1.3%). Acute adverse events also occurred at a higher rate among both first-time and repeat CCP donations compared to SA.<bold>Conclusions: </bold>CCP donors were more likely to be first-time and female donors than WB or SA donors. CCP donations had a higher rate of donor adverse reactions, deferrals, and product loss than SA donations.
- Subjects
AMERICAN Red Cross; CONVALESCENT plasma; COVID-19; DIAGNOSTIC use of polymerase chain reaction; HLA histocompatibility antigens; COVID-19 treatment
- Publication
Transfusion, 2021, Vol 61, Issue 5, p1471
- ISSN
0041-1132
- Publication type
journal article
- DOI
10.1111/trf.16286